Boehringer Ingelheim announces 2018 BVDzero Case Awards

Ingelheim, Germany, 28 March 2018 – Boehringer Ingelheim is announcing the 2018 ‘BVDzero Case Awards’ which are now open for application. The biennal awards reflect Boehringer Ingelheim’s long-term commitment to promoting the health and well-being of farm animals.

“Bovine viral diarrhea virus (BVDV) is one of the most common diseases in cattle, causing harm to the affected animals and huge economic damage to the livestock industry. We aim to challenge the status quo and bring a paradigm shift in the control of BVD,” said Steve Williams, Head of Global Ruminants/Cattle Strategic Business Unit at Boehringer Ingelheim.

Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered. Any person involved in the cattle industry in Europe (excluding Belgium) and Brazil is eligible for participation. Areas of expertise include, but are not limited to, research, diagnostics, animal science, veterinary practice, production veterinary medicine, cattle production and animal health and welfare.

Through the ‘BVDzero Case Awards’, Boehringer Ingelheim aims to encourage the search for both clinical and subclinical cases of BVD in cattle herds. The company believes that it will help to increase the awareness of BVD and, as a result, help to reduce its prevalence.
Submissions for the award will be open until 30 June 2018. Application forms and criteria can be found on www.bvdzero.com  

The award ceremony will take place at this year’s BVDzero Press Conference which will be held in Barcelona, Spain on 23 October 2018. The winners of the award will be selected by the BVDzero Committee, consisting of renowned external experts in the field of bovine health.

Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com

About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.